Calmark receives Notice of Allowance regarding patent in USA
Calmark Sweden AB (publ) announces today that the US Patent Office ("USPTO") has issued a Notice of Allowance regarding Calmark's POC system.
The patent, entitled "Detection of a biomarker in a sample of a flowable substance" and application number 16/477143, covers the entire POC system and the method of detecting a biomarker in eg blood. The patent provides protection until 2038. The Notice of Allowance means that the USPTO will approve the company's patent application.
Including the new patent, Calmark owns seventeen patents and design protection for both the instrument and the test cassette on important markets.
"Today's news is gratifying," says Anna Söderlund, CEO of Calmark. “For Calmark, it is strategically important to have broad patent protection for the company's technologies and methods, it protects us from competition and plagiarism. We work continuously to file patents for our innovations.”
Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.
For more information about Calmark Sweden AB, please contact:
Anna Söderlund, CEO
Telefon: +46 70 214 98 93
E-post: anna.soderlund@calmark.se
www.calmark.se
Calmark Sweden AB is a medical technology company that develops and markets a point-of-care (POC) analysis method with easier and faster diagnostics of medical conditions in newborns. The unique test platform consists of a portable instrument and test cassettes for various biomarkers. The first test, Neo-Bilirubin, was launched to the market in 2020. In the Western world, the introduction of POC diagnostics is resulting in huge savings and shorter care chains. In less developed healthcare systems, the product will offer a decision support which is currently lacking, since the access to hospital laboratories often is limited. Calmark aims to become the global leader in POC diagnostics for newborns and, in the long term, to offer all relevant tests for the first period of life. In addition to products for newborns, Calmark sells a POC test for assessment of COVID-19 disease severity. The B share is listed on the Spotlight Stock Market and is traded under the CALMA B ticker. Read more at www.calmark.se/eng/home.